Aligos Therapeutics (ALGS) announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls, effective immediately. Prior to joining Aligos Therapeutics, Dr. Wesson served in positions of increasing responsibility, including as the Head of CMC and Supply Chain at Kezar Life Sciences and AN2 Therapeutics.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule
- Aligos Therapeutics appoints Laura Kavanaugh as VP, head of legal
- Aligos Therapeutics presents data at EASL Congress 2025
- Aligos Therapeutics Reports Strong Q1 2025 Progress
- Aligos Therapeutics reports Q1 EPS ($2.11), consensus ($3.15)